Last reviewed · How we verify
NCT03494894: BAVASI
Bacteriological Link Between Upper and Lower Airways in Cystic Fibrosis and Primary Ciliary Dyskinesia
trial testing Middle meatus aspirations and sputum in Cystic Fibrosis in 120 participants. Completed in 19 February 2019.
14 June 2017
Quick facts
| Lead sponsor | Centre Hospitalier Intercommunal Creteil |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 1 June 2017 |
| Primary completion | 14 June 2017 |
| Estimated completion | 19 February 2019 |
| Sites | 1 location across France |
Drugs / interventions tested
- Middle meatus aspirations and sputum
Conditions studied
- Cystic Fibrosis — all drugs for Cystic Fibrosis →
- Primary Ciliary Dyskinesia — all drugs for Primary Ciliary Dyskinesia →
Sponsor
Centre Hospitalier Intercommunal Creteil
Who can join
6 and older, any sex, with Cystic Fibrosis or Primary Ciliary Dyskinesia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cytobacteriological examination of sputum and bacteriological sampling in the middle meatus.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Follow-Up and Management of Chronic Rhinosinusitis in Adults with Primary Ciliary Dyskinesia: Review and Experience of Our Reference Centers.
Bequignon E, Dupuy L, Escabasse V, Zerah-Lancner F, et al · · 2019 · cited 12× · PMID 31546861 · DOI 10.3390/jcm8091495
Verify or expand the search:
- PubMed search for NCT03494894
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cystic Fibrosis
Currently open trials in the same condition.
- NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
- NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
- NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
- NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
- NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting
Other Centre Hospitalier Intercommunal Creteil trials
Trials by the same sponsor.
- NCT07493785 — Dexmedetomidine for Invasive Ventilation In the NEOnate · Phase 2, PHASE3 · not yet recruiting
- NCT07513051 — DIaphragmatic Swing According to Cpap Flow Output in NEOnates (DISCONEO) · NA · not yet recruiting
- NCT07455942 — Towards an Understanding of Barriers and Delays in the Diagnosis of Anal Cancer · not yet recruiting
- NCT07153367 — Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauter · Phase 2 · recruiting
- NCT06339450 — Real World Environmental Exposure Study With Healthy and Cystic Fibrosis Subjects · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03494894 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Intercommunal Creteil
- Last refreshed: 4 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03494894.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing